Navigation Links
Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
Date:10/19/2009

d hemostasis. For more information, please visit: www.talecris.com.

Cautionary statement regarding forward-looking statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, quotations from management in this press release, statements regarding strategic and operation plans, and statements regarding the development or commercialization of therapies. Forward-looking statements are based

The following factors, among others, could cause actual results to differ materially from those expressed or implied in forward-looking on current beliefs and expectations and are subject to inherent risks and uncertainties. You are cautioned not to place undue reliance on forward-looking statements. Although Talecris believes that the forward-looking statements contained in this press release are reasonable, there is no assurance that expectations will be fulfilled. statements: possible U.S. legislation or regulatory action affecting, among other things, the U.S. healthcare system, pharmaceutical pricing and reimbursement, including Medicaid and Medicare; our ability to procure adequate quantities of plasma and other materials which are acceptable for use in our manufacturing processes from our own plasma collection centers or from third-party vendors; our ability to maintain compliance with government regulations and licenses, including those related to plasma collection, production and marketing; our ability to identify growth opportunities for existing products and our ability to identify and develop new product candidates through our research and development activities; and the timing of, and our ability to, obtain and/or maintain regulatory approvals for new product candidates, the rate and degree of market acceptance, and the
'/>"/>

SOURCE Talecris Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
3. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
4. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
7. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
8. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
9. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by AstraZeneca ... is an important drug for the treatment of ... 2000, quetiapine was listed in the Catalogue of ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... At the end of 2009, the vaccine industry raised ... business media were occupied by various kinds of news ... successfully landed on the Nasdaq, then Simcere, a pharmaceutical ... announced a 50.8% stake in Ealong Biotech and took ...
... EAST HANOVER, N.J., Oct. 16 Novartis announced today ... safety profile of once-yearly Reclast® (zoledronic acid) injection in ... 1,200 women was presented this weekend at the annual ... Research (ASBMR) in Toronto, ON, Canada. The ...
Cached Medicine Technology:Vaccine Leaders All Over the World Talking About China Vaccine Opportunities at VacChina 2010 -- the No.1 China Focused Vaccine Partnering Forum 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 3Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 4Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 5Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 6
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest travel ... in Healthcare by Modern Healthcare and will be honored at an awards dinner ... year, the Best Places to Work in Healthcare program recognizes outstanding employers in the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice ... low cost. Personalized with practice contact information and logos, Calendars stand alone as ... also incorporate Calendars into seasonal mailings, thank you and welcome communications, and to ...
(Date:8/28/2015)... ... 28, 2015 , ... Northridge dentists Dr. Elyson and Dr. Assili ... patients can currently receive a one hour treatment of this teeth whitening option. ... a number of unique features that can turn teeth up to nine shades whiter. ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an ... coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s ... Extraction™ technology, which delivers a variety of sizes and styles while achieving the ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... of California, chemists have taken snapshots of the ... professor of chemistry at the UC Berkeley, reported ... than the width of a human hair an ... generated great excitement in the opto-electronics community because ...
... strategy was developed - using a natural compound to ... in the cellular reservoirs of the body. Prostratin, an ... stimulate the virus, which causes AIDS, in a way ... attack it.// , Dr. Roger Pomerantz, chief of ...
... to a study, exercise can help older people avert ... such as standing up and walking an impossible one.Those ... likely to lose abilities to perform activities of daily ... of Medicine, Texas, this report is the first to ...
... identified a gene that causes benign moles on the skin ... effectively patients with early stages of melanoma. ,A ... Hopkins University, found a gene known as Id1 that causes ... suppressor gene that ordinarily keeps precancerous moles from progressing to ...
... developed by Australians which may replace the PAP smear, it ... well as Australia. ,Sydney-based Polartechnics Ltd has developed the ... it offers instant results and greater ccuracy than PAP smears. ... directly from the cervix about the colour// and electrical properties ...
... the development of an artificial vision system for a ... acuity of about 20/400. ,The system uses ... both of which are mounted on a pair of ... miniature computer which is worn on a belt. After ...
Cached Medicine News:Health News:Discovery of World’s smallest laser 2Health News:Prostratin- Drug to eradicate HIV 2Health News:Arthritis risk reduced by exercise 2Health News:Gene causes moles to become cancerous 2
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
Posterior Capsule Polisher, 23 g., 30 angle small gauge with roughened tip, open end port. Overall length 16 mm. 5/box....
Medicine Products: